Rationale for the evaluation of fluoxetine in the treatment of enterovirus d68-associated acute flaccid myelitis

JAMA Neurology

Volumn 72, Issue 5, 2015, Pages 493-494

  Tyler, Kenneth L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; FLUOXETINE; PROTEIN 2C; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE FLACCID MYELITIS; BINDING AFFINITY; BINDING SITE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; ENTEROVIRUS; ENTEROVIRUS D68; ENTEROVIRUS INFECTION; HUMAN; MOLECULAR DYNAMICS; MYELITIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN RNA BINDING; VIRUS INHIBITION; ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; DRUG DEVELOPMENT; ENTEROVIRUS D; MUSCLE HYPOTONIA; PATHOGENICITY; VIROLOGY;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; DRUG DISCOVERY; ENTEROVIRUS D, HUMAN; FLUOXETINE; HUMANS; MUSCLE HYPOTONIA; MYELITIS;

EID: 84938533620     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.4625     Document Type: Note

References (10)

1. Ayscue P, Van Heren K, Sheriff H, et al; Centers for Disease Control and Prevention (CDC). Acute flaccid paralysis with anterior myelitis-California, June 2012-June2014. MMWR Morb Mortal Wkly Rep. 2014;63(40):903-906.
2. Centers for Disease Control and Prevention. Enterovirus D68 for health care professionals. 2014. http://www.cdc.gov/non-polio-enterovirus/hcp/EV-D68-hcp. html. Accessed December 15, 2014.
3. Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence NV. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak [published online November 20, 2014]. AJNR Am J Neuroradiol. doi:10.3174/ajnr. A4188.
4. Pastula DM, Aliabadi N, Haynes AK, et al; Centers for Disease Control and Prevention (CDC). Acute neurologic illness of unknown etiology in children-Colorado, August-September 2014. MMWR Morb Mortal Wkly Rep. 2014;63(40):901-902.
5. Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother. 2012;56(9):4838-4844.
6. Ulferts R, van der Linden L, Thibaut HJ, et al. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother. 2013;57(4):1952-1956.
7. De Palma AM, Heggermont W, Lanke K, et al. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol. 2008;82(10):4720-4730.
8. Wilens TE, Cohen L, Biederman J, et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol. 2002;22(6):568-575.
9. Karson CN, Newton JE, Livingston R, et al. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993;5(3):322-329.
10. Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry. 2002;159(5):755-760.